In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 141 to 150 of 293

TitleTypeExpected publication date
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidanceTBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]Technology appraisal guidanceTBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Technology appraisal guidanceTBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Technology appraisal guidanceTBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]Technology appraisal guidanceTBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]Technology appraisal guidanceTBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]Technology appraisal guidance
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All